The goal is to take a little bit of market share from the unorganised sector and grow the company’s share of the market
Roche Diagnostics India is aiming at 15 per cent share of the in-vitro diagnostics market in the next two years as part of its growth plans in the country.
Roche Diagnostics is part of Swiss healthcare major Roche. It sells devices and equipment to labs and hospitals and is mainly present in the business-to-business space.
“We are planning to have around 15 per cent of the market share in in-vitro diagnostics segment in India in next two years,” said Shravan Subramanyam, MD, India & Neighbouring Markets, Roche Diagnostics.
The goal is to take a little bit of market share from the unorganised sector and grow the company’s share of the market. The IVD industry in India is approximately worth Rs 5,000 crore, he added.
“We are also seeing consolidation of our customers, that is labs, and we would like to access tier II and tier III cities and rural markets through them and get a larger piece of the diagnostics market,” Subramanyam said.
From a strategic roadmap point of view, for the next five years, the company is looking at how to be relevant in India and so is focusing on areas such as womens health, non communicable diseases like diabetes, cardio vascular diseases, cancer and wellness segments, he added.
“But as India still has a very high burden of infectious diseases, we will continue to be in the space of infectious diseases,” Subramanyam said.
When asked if the company is planning to open a manufacturing or research and development facility in India, he said nothing in this direction was being planned at the moment.
“Our focus is on digitising pathological labs, skill building amongst existing lab technicians and ensuring that the infrastructure is suitable for world class diagnostic tests to be launched in India,” Subramanyam said.
India is definitely a significant market for the company. It is one of the high growth markets in Asia-Pacific, he added.
- Advertisement -
Comments are closed.